• Room 03.062 - CEM

    United Kingdom

Accepting PhD Students

PhD projects

Dr Chen is open to wide-range PhD applications, her fields of interest include: immunopathogenesis of age-related retinal degeneration, ocular drug delivery.

20072020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research Statement

Research topics

  • Retinal degenerative and vascular diseases, including age-related macular degeneration, diabetic retinopathy and retinitis pigmentosa.  
  •  Ocular drug delivery, in particular, topical drug delivery for retinal degenerative and angiogenic diseases.  

 

Research statement

My research has been focused on the role of inflammation in the pathogenesis of retinal degenerative and angiogenic diseases, including age-related macular degeneration (AMD), diabetic retinopathy (DR) and Retinitis Pigmentosa (RP). Although AMD, DR and RP are not classical inflammatory diseases, inflammation is known to play an important role in the initiation and progression of the diseases. We aim to understand how inflammation contributes to the aetiology of these diseases and to identify targets for therapeutic intervention.

 

Main research activities

1) Inflammation in DR: We are interested in how diabetes affects immune cells and why the immune response to diabetes-mediated retinal injury becomes detrimental in DR. During diabetes, abnormal glucose metabolism can affect the development and function of immune cells (Xu and Chen. Diabetic retinopathy and dysregulated innate immunity. Vision Research. 2017;139:39-46). We have found that prolonged high glucose environment sensitises macrophages to inflammatory stimuli, but reduces the defence function of macrophages (Pavlou, et al. Sustained high glucose exposure sensitizes macrophage responses to cytokine stimuli but reduces their phagocytic activity.BMC Immunology. 2018; Vol. 19:24).  

2) The role of Muller cell in retinal neurovascular unit: The blood-retinal barrier (BRB) is essential for retinal immune privilege. The functional integrity of BRB is maintained by the retinal neurovascular unit. Muller cell, the principal glia spanning almost the entire retina, is an important component of the neurovascular unit. We aim to understand the regulatory role of Muller cells in the neurovascular unit and BRB, and how the regulation is altered in diseases such as DR and AMD. Our group has recently established a mouse Muller cell line (Augustine, et al.  Characterization of a spontaneously immortalized murine Müller glial cell line QMMuC-1. IOVS 2018; Vol. 59, No. 3. pp. 1666-1674), which provides a valuable tool for studying the pathophysiology of Muller cells.    

3) Topical drug delivery for the treatment of retinal diseases: Due to the distinct anatomy of human eyes, it has been very difficult for topically applied drug to reach the posterior segment of the eyes. Teamed with collaborators in University of Birmingham, we have demonstrated that a cell penetrating peptide can aid drugs to the posterior segment of the eyes when applied topically (de Cogan, et al.  Topical Delivery of Anti-VEGF Drugs to the Ocular Posterior Segment Using Cell-Penetrating Peptides. IOVS 2017; Vol. 58, No. 5. pp. 2578-2590).

 

Fingerprint Dive into the research topics where Mei Chen is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 12 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

Research Output

Open Access
File
  • 23 Downloads (Pure)

    Circulating Leukocyte Alterations and the Development/Progression of Diabetic Retinopathy in Type 1 Diabetic Patients – A Pilot Study

    Obasanmi, G., Lois, N., Armstrong, D., Lavery, N. J., Romero Hombrebueno, J. M., Lynch, A., Wright, D., Chen, M. & Xu, H., 30 Jan 2020, In : Current eye research. 11 p.

    Research output: Contribution to journalArticle

  • Attenuating Diabetic Vascular and Neuronal Defects by Targeting P2rx7

    Pavlou, S., Augustine, J., Cunning, R., Harkin, K., Stitt, A. W., Xu, H. & Chen, M., 29 Apr 2019, In : International journal of molecular sciences. 20, 9, 12 p., 2101.

    Research output: Contribution to journalArticle

    Open Access
    File
  • 3 Citations (Scopus)
    95 Downloads (Pure)

    Datasets

    Dataset for Microplasma assisted synthesis of gold nanoparticle/graphene oxide nanocomposites and their potential application in SERS sensing

    Tang, M. (Creator), Zhang, L. (Creator), Falzon, B. (Creator), Padmanaban, D. B. (Creator), Mariotti, D. (Creator), Maguire, P. (Creator), Xu, H. (Creator), Chen, M. (Creator), Queen's University Belfast, 04 Jul 2019

    Dataset

    File

    Prizes

    2010 ISER International Travel Award

    Mei Chen (Recipient), Jul 2010

    Prize: Prize (including medals and awards)

    2012 Fight for Sight Early Career Investigator Award

    Mei Chen (Recipient), 2012

    Prize: Fellowship awarded competitively

    2015 ARVO International Travel Award

    Mei Chen (Recipient), May 2015

    Prize: Prize (including medals and awards)

    Travel award

    Mei Chen (Recipient), 18 Oct 2013

    Prize: Prize (including medals and awards)

    Activities

    PhD examiner for University of Strathclyde, Glasgow

    Mei Chen (Examiner)
    2019

    Activity: Examination typesPhD external examination

    Halloween Bake Sale for Fight for Sight UK

    Mei Chen (Organiser)
    31 Oct 2018

    Activity: Other activity typesOther

    XXIII Biennial Meeting of the International Society for Eye Research (ISER)

    Mei Chen (Invited speaker)
    12 Sep 2018

    Activity: Talk or presentation typesInvited or keynote talk at national or international conference

    OCUTHER Advanced course in Ophthalmology

    Mei Chen (Participant)
    Oct 2018

    Activity: Participating in or organising an event typesParticipation in workshop, seminar, course

    Project: Developing a novel antibody for the management of Diabetic Retinopathy

    Mei Chen (Consultant)
    20182019

    Activity: Consultancy typesKTP & Consultancy in kind